Back to Search Results

Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update.

Division of Cardiology, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR. Department of Medicine, University of Mississippi, Jackson, MS. Division of Cardiology, Department of Medicine, Duke University, Durham, NC; Duke Clinical Research Institute, Durham, NC. Division of Cardiology, Department of Medicine, University Texas Southwestern, and Parkland Health and Hospital System, Dallas, TX. Division of Cardiology, Department of Medicine, Duke University, Durham, NC; Duke Clinical Research Institute, Durham, NC. Electronic address: marat.fudim@duke.edu.

American heart journal. 2021;:86-91
Full text from:

Other resources

Abstract

In this report, we aim to provide an updated meta-analysis of the sodium-glucose cotransporter 2 (SGLT2) inhibitors trial data with the new trial data on sotagliflozin, a first-in-class dual SGLT1 and SGLT2 inhibitor. We searched Medline, Cochrane library, and Embase databases for randomized clinical trials comparing cardiovascular and kidney outcomes between SGLT2 and dual SGLT1/2 inhibitors and placebo. Nine randomized clinical trials with a total of 60,914 patients with type 2 diabetes were included. In patients with type 2 diabetes, the use of SGLT2 and dual SGLT1/2 inhibitors improves the cardiovascular and kidney outcome.

Methodological quality

Publication Type : Meta-Analysis

Metadata